Mucopolysaccharidosis consists of a group of more than 40 genetic disorders that forms a part of lysosomal storage disease. They are caused by an inherited deficiency of an enzyme involved in the degradation of acid glycosaminoglycans (GAGs), which was previously known as mucopolysaccharidosis. All of the mucopolysaccharidoses are rare, autosomal recessive, except for mucopolysaccharidosis III, as it is X-linked.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy for Mucopolysaccharidosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for Mucopolysaccharidosis. This report contains market size and forecasts of Gene Therapy for Mucopolysaccharidosis in global, including the following market information:
Global Gene Therapy for Mucopolysaccharidosis Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Gene Therapy for Mucopolysaccharidosis market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Over the past few years, gene therapy has emerged as one of the most exciting approaches for the treatment of mucopolysaccharidosis. One of the promising therapy is replacement gene therapy, which replaces faulty genes with normal ones in the body. It is considered to be a potential cure to mucopolysaccharidoses and a promising option in the long run.
We surveyed the Gene Therapy for Mucopolysaccharidosis companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gene Therapy for Mucopolysaccharidosis Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Gene Therapy for Mucopolysaccharidosis Market Segment Percentages, by Type, 2022 (%)
Intravenous
ICV
Intracerebral
Intracisternal
Global Gene Therapy for Mucopolysaccharidosis Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Gene Therapy for Mucopolysaccharidosis Market Segment Percentages, by Application, 2022 (%)
Mucopolysaccharidosis I
Mucopolysaccharidosis II
Mucopolysaccharidosis III A
Mucopolysaccharidosis III B
Global Gene Therapy for Mucopolysaccharidosis Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Gene Therapy for Mucopolysaccharidosis Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gene Therapy for Mucopolysaccharidosis revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Gene Therapy for Mucopolysaccharidosis revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sangamo Therapeutics
Swedish Orphan Biovitrum
uniQure
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gene Therapy for Mucopolysaccharidosis, market overview.
Chapter 2: Global Gene Therapy for Mucopolysaccharidosis market size in revenue.
Chapter 3: Detailed analysis of Gene Therapy for Mucopolysaccharidosis company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gene Therapy for Mucopolysaccharidosis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Gene Therapy for Mucopolysaccharidosis Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gene Therapy for Mucopolysaccharidosis Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gene Therapy for Mucopolysaccharidosis Overall Market Size
2.1 Global Gene Therapy for Mucopolysaccharidosis Market Size: 2022 VS 2029
2.2 Global Gene Therapy for Mucopolysaccharidosis Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Gene Therapy for Mucopolysaccharidosis Players in Global Market
3.2 Top Global Gene Therapy for Mucopolysaccharidosis Companies Ranked by Revenue
3.3 Global Gene Therapy for Mucopolysaccharidosis Revenue by Companies
3.4 Top 3 and Top 5 Gene Therapy for Mucopolysaccharidosis Companies in Global Market, by Revenue in 2022
3.5 Global Companies Gene Therapy for Mucopolysaccharidosis Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gene Therapy for Mucopolysaccharidosis Players in Global Market
3.6.1 List of Global Tier 1 Gene Therapy for Mucopolysaccharidosis Companies
3.6.2 List of Global Tier 2 and Tier 3 Gene Therapy for Mucopolysaccharidosis Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Gene Therapy for Mucopolysaccharidosis Market Size Markets, 2022 & 2029
4.1.2 Intravenous
4.1.3 ICV
4.1.4 Intracerebral
4.1.5 Intracisternal
4.2 By Type - Global Gene Therapy for Mucopolysaccharidosis Revenue & Forecasts
4.2.1 By Type - Global Gene Therapy for Mucopolysaccharidosis Revenue, 2018-2023
4.2.2 By Type - Global Gene Therapy for Mucopolysaccharidosis Revenue, 2024-2029
4.2.3 By Type - Global Gene Therapy for Mucopolysaccharidosis Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Gene Therapy for Mucopolysaccharidosis Market Size, 2022 & 2029
5.1.2 Mucopolysaccharidosis I
5.1.3 Mucopolysaccharidosis II
5.1.4 Mucopolysaccharidosis III A
5.1.5 Mucopolysaccharidosis III B
5.2 By Application - Global Gene Therapy for Mucopolysaccharidosis Revenue & Forecasts
5.2.1 By Application - Global Gene Therapy for Mucopolysaccharidosis Revenue, 2018-2023
5.2.2 By Application - Global Gene Therapy for Mucopolysaccharidosis Revenue, 2024-2029
5.2.3 By Application - Global Gene Therapy for Mucopolysaccharidosis Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Gene Therapy for Mucopolysaccharidosis Market Size, 2022 & 2029
6.2 By Region - Global Gene Therapy for Mucopolysaccharidosis Revenue & Forecasts
6.2.1 By Region - Global Gene Therapy for Mucopolysaccharidosis Revenue, 2018-2023
6.2.2 By Region - Global Gene Therapy for Mucopolysaccharidosis Revenue, 2024-2029
6.2.3 By Region - Global Gene Therapy for Mucopolysaccharidosis Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Gene Therapy for Mucopolysaccharidosis Revenue, 2018-2029
6.3.2 US Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.3.3 Canada Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.3.4 Mexico Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Gene Therapy for Mucopolysaccharidosis Revenue, 2018-2029
6.4.2 Germany Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.4.3 France Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.4.4 U.K. Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.4.5 Italy Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.4.6 Russia Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.4.7 Nordic Countries Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.4.8 Benelux Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Gene Therapy for Mucopolysaccharidosis Revenue, 2018-2029
6.5.2 China Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.5.3 Japan Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.5.4 South Korea Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.5.5 Southeast Asia Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.5.6 India Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Gene Therapy for Mucopolysaccharidosis Revenue, 2018-2029
6.6.2 Brazil Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.6.3 Argentina Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Gene Therapy for Mucopolysaccharidosis Revenue, 2018-2029
6.7.2 Turkey Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.7.3 Israel Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.7.4 Saudi Arabia Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
6.7.5 UAE Gene Therapy for Mucopolysaccharidosis Market Size, 2018-2029
7 Gene Therapy for Mucopolysaccharidosis Companies Profiles
7.1 Sangamo Therapeutics
7.1.1 Sangamo Therapeutics Company Summary
7.1.2 Sangamo Therapeutics Business Overview
7.1.3 Sangamo Therapeutics Gene Therapy for Mucopolysaccharidosis Major Product Offerings
7.1.4 Sangamo Therapeutics Gene Therapy for Mucopolysaccharidosis Revenue in Global Market (2018-2023)
7.1.5 Sangamo Therapeutics Key News & Latest Developments
7.2 Swedish Orphan Biovitrum
7.2.1 Swedish Orphan Biovitrum Company Summary
7.2.2 Swedish Orphan Biovitrum Business Overview
7.2.3 Swedish Orphan Biovitrum Gene Therapy for Mucopolysaccharidosis Major Product Offerings
7.2.4 Swedish Orphan Biovitrum Gene Therapy for Mucopolysaccharidosis Revenue in Global Market (2018-2023)
7.2.5 Swedish Orphan Biovitrum Key News & Latest Developments
7.3 uniQure
7.3.1 uniQure Company Summary
7.3.2 uniQure Business Overview
7.3.3 uniQure Gene Therapy for Mucopolysaccharidosis Major Product Offerings
7.3.4 uniQure Gene Therapy for Mucopolysaccharidosis Revenue in Global Market (2018-2023)
7.3.5 uniQure Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Gene Therapy for Mucopolysaccharidosis Market Opportunities & Trends in Global Market
Table 2. Gene Therapy for Mucopolysaccharidosis Market Drivers in Global Market
Table 3. Gene Therapy for Mucopolysaccharidosis Market Restraints in Global Market
Table 4. Key Players of Gene Therapy for Mucopolysaccharidosis in Global Market
Table 5. Top Gene Therapy for Mucopolysaccharidosis Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Gene Therapy for Mucopolysaccharidosis Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Gene Therapy for Mucopolysaccharidosis Revenue Share by Companies, 2018-2023
Table 8. Global Companies Gene Therapy for Mucopolysaccharidosis Product Type
Table 9. List of Global Tier 1 Gene Therapy for Mucopolysaccharidosis Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Gene Therapy for Mucopolysaccharidosis Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Gene Therapy for Mucopolysaccharidosis Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Gene Therapy for Mucopolysaccharidosis Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Gene Therapy for Mucopolysaccharidosis Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Gene Therapy for Mucopolysaccharidosis Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Gene Therapy for Mucopolysaccharidosis Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Gene Therapy for Mucopolysaccharidosis Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2024-2029
Table 30. Sangamo Therapeutics Company Summary
Table 31. Sangamo Therapeutics Gene Therapy for Mucopolysaccharidosis Product Offerings
Table 32. Sangamo Therapeutics Gene Therapy for Mucopolysaccharidosis Revenue (US$, Mn) & (2018-2023)
Table 33. Sangamo Therapeutics Key News & Latest Developments
Table 34. Swedish Orphan Biovitrum Company Summary
Table 35. Swedish Orphan Biovitrum Gene Therapy for Mucopolysaccharidosis Product Offerings
Table 36. Swedish Orphan Biovitrum Gene Therapy for Mucopolysaccharidosis Revenue (US$, Mn) & (2018-2023)
Table 37. Swedish Orphan Biovitrum Key News & Latest Developments
Table 38. uniQure Company Summary
Table 39. uniQure Gene Therapy for Mucopolysaccharidosis Product Offerings
Table 40. uniQure Gene Therapy for Mucopolysaccharidosis Revenue (US$, Mn) & (2018-2023)
Table 41. uniQure Key News & Latest Developments
List of Figures
Figure 1. Gene Therapy for Mucopolysaccharidosis Segment by Type in 2022
Figure 2. Gene Therapy for Mucopolysaccharidosis Segment by Application in 2022
Figure 3. Global Gene Therapy for Mucopolysaccharidosis Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Gene Therapy for Mucopolysaccharidosis Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Gene Therapy for Mucopolysaccharidosis Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Gene Therapy for Mucopolysaccharidosis Revenue in 2022
Figure 8. By Type - Global Gene Therapy for Mucopolysaccharidosis Revenue Market Share, 2018-2029
Figure 9. By Application - Global Gene Therapy for Mucopolysaccharidosis Revenue Market Share, 2018-2029
Figure 10. By Type - Global Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Gene Therapy for Mucopolysaccharidosis Revenue Market Share, 2018-2029
Figure 12. By Application - Global Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Gene Therapy for Mucopolysaccharidosis Revenue Market Share, 2018-2029
Figure 14. By Region - Global Gene Therapy for Mucopolysaccharidosis Revenue Market Share, 2018-2029
Figure 15. By Country - North America Gene Therapy for Mucopolysaccharidosis Revenue Market Share, 2018-2029
Figure 16. US Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Gene Therapy for Mucopolysaccharidosis Revenue Market Share, 2018-2029
Figure 20. Germany Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 21. France Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Gene Therapy for Mucopolysaccharidosis Revenue Market Share, 2018-2029
Figure 28. China Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 32. India Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Gene Therapy for Mucopolysaccharidosis Revenue Market Share, 2018-2029
Figure 34. Brazil Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Gene Therapy for Mucopolysaccharidosis Revenue Market Share, 2018-2029
Figure 37. Turkey Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Gene Therapy for Mucopolysaccharidosis Revenue, (US$, Mn), 2018-2029
Figure 41. Sangamo Therapeutics Gene Therapy for Mucopolysaccharidosis Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Swedish Orphan Biovitrum Gene Therapy for Mucopolysaccharidosis Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. uniQure Gene Therapy for Mucopolysaccharidosis Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
